CRYOPORT, INC. Operating Lease, Expense
CRYOPORT, INC. (CYRX) reported Operating Lease, Expense of $2.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- CRYOPORT, INC. operating lease, expense for the quarter ending 2026-06-30 was $1.20M, a 43.51% decline year-over-year.
- CRYOPORT, INC. operating lease, expense for the quarter ending 2026-03-31 was $1.24M, a 35.27% decline year-over-year.
- CRYOPORT, INC. operating lease, expense for the quarter ending 2025-12-31 was $1.29M, a 6.31% decline year-over-year.
- CRYOPORT, INC. operating lease, expense for the quarter ending 2025-09-30 was $1.27M, a 19.04% decline year-over-year.
- CRYOPORT, INC. operating lease, expense for fiscal 2025 was $6.60M, a 14.32% increase from fiscal 2024.
- CRYOPORT, INC. operating lease, expense for fiscal 2024 was $5.77M, a 13.07% increase from fiscal 2023.
- CRYOPORT, INC. operating lease, expense for fiscal 2023 was $5.10M, a 40.00% increase from fiscal 2022.
- CRYOPORT, INC. operating lease, expense for fiscal 2022 was $3.65M, a 8.26% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.44M 10-Q · filed 2026-08-06 | $3.73M derived: sum of 3 quarters · filed 2026-08-06 | $5.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.24M 10-Q · filed 2026-05-05 | $2.53M derived: sum of 2 quarters · filed 2026-05-05 | $3.80M derived: sum of 3 quarters · filed 2026-05-05 | $5.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.56M derived: sum of 2 quarters · filed 2026-03-05 | $4.68M derived: sum of 3 quarters · filed 2026-08-06 | $6.60M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.39M derived: sum of 2 quarters · filed 2026-08-06 | $5.30M 10-Q · filed 2025-11-06 | $6.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.04M 10-Q · filed 2026-08-06 | $5.42M derived: sum of 3 quarters · filed 2026-08-06 | $6.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.91M 10-Q · filed 2026-05-05 | $3.29M derived: sum of 2 quarters · filed 2026-05-05 | $4.86M derived: sum of 3 quarters · filed 2026-05-05 | $6.32M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.94M derived: sum of 2 quarters · filed 2026-03-05 | $4.41M derived: sum of 3 quarters · filed 2026-03-05 | $5.77M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.03M derived: sum of 2 quarters · filed 2025-11-06 | $4.39M 10-Q · filed 2025-11-06 | $6.09M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.83M 10-Q · filed 2025-08-12 | $4.53M derived: sum of 3 quarters · filed 2026-03-05 | $5.65M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $1.36M 10-Q · filed 2025-05-08 | $3.06M derived: sum of 2 quarters · filed 2026-03-05 | $4.18M derived: sum of 3 quarters · filed 2026-03-05 | $5.36M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.82M derived: sum of 2 quarters · filed 2026-03-05 | $4.00M derived: sum of 3 quarters · filed 2026-03-05 | $5.10M 10-K · filed 2026-03-05 |
| 2023-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.30M derived: sum of 2 quarters · filed 2024-11-07 | $3.40M 10-Q · filed 2024-11-07 | $4.36M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.28M 10-Q · filed 2024-08-08 | $3.24M derived: sum of 3 quarters · filed 2025-03-07 | $4.09M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-08 | $2.06M derived: sum of 2 quarters · filed 2025-03-07 | $2.91M derived: sum of 3 quarters · filed 2025-03-07 | $3.85M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $957.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $1.81M derived: sum of 2 quarters · filed 2025-03-07 | $2.75M derived: sum of 3 quarters · filed 2025-03-07 | $3.65M 10-K · filed 2025-03-07 |
| 2022-09-30 | $854.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.79M derived: sum of 2 quarters · filed 2023-11-09 | $2.69M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $938.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.83M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $896.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $3.37M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |